

Characterization and Synthesis of Eudistidine C, a Bioactive Marine Alkaloid with an Intriguing Molecular Scaffold

Susanna T. S. Chan,[†] Roger R. Nani,[‡] Evan A. Schauer,^{‡,&} Gary E. Martin,[§] R. Thomas Williamson,[§] Josep Saurí,[§] Alexei V. Buevich,[§] Wes A. Schafer,[§] Leo A. Joyce,[§] Andrew K. L. Goey,^{||} William D. Figg,^{||} Tanya T. Ransom,[†] Curtis J. Henrich,^{†,⊥} Tawnya C. McKee,^{†,§} Arvin Moser,^Δ Scott A. MacDonald,^Δ Shabana Khan,[⊗] James B. McMahon,[†] Martin J. Schnermann,^{*,‡} and Kirk R. Gustafson^{*,†}

[†]Molecular Targets Laboratory, Center for Cancer Research and [‡]Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States

[§]NMR Structure Elucidation, Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States

^{||}Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States


[⊥]Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States

^ΔAdvanced Chemistry Development, Inc. (ACD/Laboratories), Toronto Department, 8 King Street East Suite 107, Toronto, Ontario M5C 1B5, Canada

[⊗]National Center for Natural Products Research, School of Pharmacy, University of Mississippi, Mississippi 38677, United States

Supporting Information

ABSTRACT: An extract of *Eudistoma* sp. provided eudistidine C (1), a heterocyclic alkaloid with a novel molecular framework. Eudistidine C (1) is a racemic natural product composed of a tetracyclic core structure further elaborated with a *p*-methoxyphenyl group and a phenol-substituted aminoimidazole moiety. This compound presented significant structure elucidation challenges due to the large number of heteroatoms and fully substituted carbons. These issues were mitigated by application of a new NMR pulse sequence (LR-HSQMBC) optimized to detect four- and five-bond heteronuclear correlations and the use of computer-assisted structure elucidation software. Synthesis of eudistidine C (1) was accomplished in high yield by treating eudistidine A (2) with 4(2-amino-1*H*-imidazol-5-yl)phenol (4) in DMSO. Synthesis of eudistidine C (1) confirmed the proposed structure and provided material for further biological characterization. Treatment of 2 with various nitrogen heterocycles and electron-rich arenes provided a series of analogues (5–10) of eudistidine C. Chiral-phase HPLC resolution of epimeric eudistidine C provided (+)-(R)-eudistidine C (1a) and (–)-(S)-eudistidine C (1b). The absolute configuration of these enantiomers was assigned by ECD analysis. (–)-(S)-Eudistidine C (1b) modestly inhibited interaction between the protein binding domains of HIF-1α and p300. Compounds 1, 2, and 6–10 exhibited significant antimalarial activity against *Plasmodium falciparum*.



INTRODUCTION

Natural products benefit from “privileged” structures that evolved to interact with essential biopolymers such as proteins and nucleic acids. These secondary metabolites encompass extensive diversity in terms of both their molecular architecture and biological activity and remain a key source of lead compounds and new therapeutic agents.¹ Nitrogen-rich natural products represent a broad class of bioactive compounds that interact with important cellular targets, particularly in the context of anticancer and anti-infective agents.^{2–4} Some recent examples of nitrogenous metabolites include the myxobacterial cytotoxin haprolid,⁵ the synoxazolidinones, antimicrobial guanidine alkaloids from a marine ascidian,⁶ the antimalarial

β -lactam monamphilectine A,⁷ and odoamide, a cytotoxic cyclic peptide from a cyanobacterium.⁸ There has been significant progress with new genomic tools that enable sequencing-based recognition and annotation of natural products with known biosynthetic machineries, and the structures of encoded secondary metabolites can often be accurately predicted.^{9–11} However, the identification of completely new molecular scaffolds such as complex polycyclic alkaloids cannot typically be accomplished using genomic methods alone. Such discoveries often depend on approaches

Received: September 29, 2016

Published: November 8, 2016

utilizing activity-guided fractionation and de novo structural elucidation. In this area, NMR-based structural studies of severely mass-limited samples on the nanomole scale have been facilitated by a new generation of miniaturized cryogenically cooled NMR probes^{12–14} and the development of sensitivity enhanced NMR pulse sequences.^{15–18} There has also been dramatic progress in the development of computational approaches that provide predictive structure determination derived from experimental data.^{19–22} The work described herein illustrates a range of contemporary structural elucidation strategies and techniques, including total synthesis. These were applied in a concerted fashion in the context of the novel heterocyclic alkaloid, eudistidine C (**1**).

We recently reported the isolation, structural elucidation, and synthesis of eudistidines A (**2**) and B (**3**) from an extract of the marine ascidian *Eudistoma* sp.²³ The extract was chemically investigated because it showed activity in a high-throughput screen for inhibitors of the protein–protein interaction between p300 and HIF-1 α . We found that **2**, but not **3**, inhibited this interaction. In the current study, we further interrogated the same extract and identified a related compound that exhibits increased chemical complexity. This compound maintains the tetracyclic core of **2** but is further elaborated at the C-10 position with an unusual aryl-substituted aminoimidazole moiety. Structure elucidation of **1** was complicated by the proton-deficient core of the molecule. The assignment was accomplished using a combination of NMR spectroscopic analyses, including a new pulse sequence specifically optimized for long-range heteronuclear correlations and structure predictive software. Synthetic studies confirmed the structure of eudistidine C (**1**) and revealed that a variety of electron-rich arenes can react with **2** under mild conditions to provide a series of aryl-substituted analogues. Chiral resolution of racemic **1** provided the two C-10 epimers, and only (–)-(S)-eudistidine C (**1b**) had significant activity in the p300 and HIF-1 α assay. In total, these studies illustrate the utility of applying synergistic technologies in concert to characterize the chemical and biological diversity of new secondary metabolites.

RESULTS AND DISCUSSION

Our initial bioassay-guided fractionation of the *Eudistoma* sp. extract provided eudistidines A (**2**) and B (**3**).²³ Further investigation of a side fraction from this effort revealed a ¹H NMR signature indicative of a related eudistidine analogue. Repeated chromatographic separations on LH-20 media ultimately provided 10.7 mg of eudistidine C (**1**).

Eudistidine C (**1**) was isolated as an optically inactive yellow oil with a molecular formula of C₂₈H₂₁N₇O₂, as established by HRESI mass spectrometry, which required 22 degrees of unsaturation. The highly aromatic nature of **1** was confirmed by 26 sp² carbons (δ_C 167.5, 161.7, 159.5, 159.3, 157.3, 148.0, 147.4, 147.0, 136.5, 131.9, 130.9, 130.2, 129.8, 129.7, 127.5, 126.1, 126.0, 117.6, 115.7, 115.2, 115.2, 94.3) and only two sp³ carbons (δ_C 73.7 and 55.8) in the ¹³C NMR spectrum (Table 1). ¹H NMR (CD₃OD) revealed signals attributable to one methoxy group (δ_H 3.76) and 14 aromatic protons, which constituted four protonated spin systems based on COSY data: a pair of mutually coupled heteroaromatic protons [δ_H 8.45 (d, J = 5.0 Hz), 6.77 (d, J = 5.3 Hz)], a 1,2-disubstituted benzene ring [δ_H 8.06 (d, J = 8.0 Hz), 7.81 (t, J = 7.5 Hz), 7.65 (d, J = 8.0 Hz), 7.58 (t, J = 7.5 Hz)], and two *para*-substituted benzene rings [δ_H 7.68 (2H d, J = 8.9 Hz), 6.91 (2H d, J = 8.8 Hz) and 6.85 (2H d, J = 8.8 Hz),




Table 1. NMR Spectroscopic Data for Eudistidine C (**1**) in CD₃OD

position	δ_C	δ_N^a	δ_H (mult/ J in Hz)	HMBC ^b
1		245.8		
2	167.5		8.45 (d, 5.0)	1, 3, 3a, 3b, 8c
3	94.3		6.77 (d, 5.3)	1, 2, 3a, 3b, 8b
3a	147.4			
3b	117.6			
4	126.1		8.06 (d, 8.0)	3a, 6, 7a
5	130.2		7.58 (t, 7.5)	3b, 7
6	136.5		7.81 (t, 7.5)	4, 7a
7	129.7		7.65 (d, 8.0)	3b, 5, 8
7a	147.0			
8		256.0		
8a	159.5			
8b		169.6		
8c	157.3			
9		n.o. ^c		
10	73.7			
11	130.9			
12/16	129.8		7.68 (d, 8.9)	10, 12/16, 14
13/15	115.2		6.91 (d, 8.8)	11, 13/15, 14
14	161.7			
14-OMe	55.8		3.76 (s)	14
17	126.1			
18		n.o. ^c		
19	148.0			
20		n.o. ^c		
21	127.5			
22	120.0			
23/27	131.9		6.85 (d, 8.8)	21, 23/27, 25
24/26	115.7		6.30 (d, 8.5)	22, 24/26, 25
25	159.3			
28		n.o. ^c		

^a¹⁵N assignments were based on ¹H–¹⁵N HMBC correlations. The δ_N values were not calibrated to an external standard but were referenced to neat NH₃ (δ 0.00) using the standard Bruker parameters. ^b¹H–¹³C (optimized for 8.3 Hz) and ¹H–¹⁵N (optimized for 8 Hz) HMBC correlations are listed. ^cNot observed.

6.30 (2H d, J = 8.5 Hz)]. Direct comparison of the 1D and 2D NMR data sets for eudistidine C (**1**) with those recorded for eudistidines A (**2**) and B (**3**) supported the presence of the same tetracyclic eudistidine core structure (rings A–D), composed of fused pyrimidine and imidazole rings with

embedded guanidine and amidine functionalities (Figure 1 and the Supporting Information). However, the chemical shift of C-




Figure 1. Selected ^1H – ^{13}C HMBC (black arrows), ^1H – ^{15}N (red arrows), and COSY (bold blue lines) correlations for eudistidine C (1).

10 in **1** (δ_{C} 73.7) differed significantly from the C-10 hemiaminal (δ_{C} 94.4) in eudistidine A (**2**) and amide (δ_{C} 172.0) in eudistidine B (**3**). HMBC correlations established that ring E in **1** was a *p*-methoxybenzene ring that was substituted at C-10 (Figure 1). The remaining *para*-substituted benzene ring (G) had a resonance at δ_{C} 159.1 that was indicative of a hydroxyl substituent.

With the tetracyclic eudistidine core and two *para*-substituted phenyl groups firmly established, molecular formula considerations required the final structure of eudistidine C (**1**) incorporate an additional $\text{C}_3\text{H}_3\text{N}_3$ moiety and 3 degrees of unsaturation. The three remaining carbons were quaternary sp^2 carbons with chemical shifts of δ_{C} 148.0, 127.5, 126.1. The only HMBC correlation to these carbons was a correlation from H-23/27 (δ_{H} 6.85) to the carbon at δ_{C} 127.5, which revealed that ring G was connected to the C_3 fragment at this position. No NH protons were ever observed using a variety of different NMR experiments (^1H , ^1H – ^{15}N HSQC, ^1H – ^{15}N HMBC) and deuterated solvents (CD_3OH , $\text{DMSO}-d_6$, $\text{DMF}-d_7$). The carbon chemical shifts, in particular the signal at δ_{C} 148.0, suggested the remaining fragment was an amino-substituted imidazole ring (ring F) connected via the carbon at δ_{C} 126.1 to C-10 and to ring G through the carbon at δ_{C} 127.5. Thus, the novel heptacyclic structure of eudistidine C (**1**) was proposed. However, significant structural ambiguity remained due to the large number of adjacent quaternary carbons and non-protonated nitrogen atoms, along with the lack of observable NH signals. The experimental ^{13}C NMR data recorded with eudistidine C (**1**) were compared with the DFT-calculated theoretical carbon chemical shifts for structure **1**. The computational results were generally in good agreement with the experimentally derived data (Supporting Information), with the largest outliers being carbons, C-11 and C-19, which had $\Delta\delta$ values of 3.8 and 4.5 ppm, respectively. The molecular formula and complete set of NMR data (^1H , ^{13}C , COSY, HSQC, HMBC) recorded for **1** were then analyzed using ACD/Structure Elucidator Suite software, which allows for de novo structure elucidation and generates a complete set of structures that fit the correlations observed in the experimental data.^{21,22} The program generated a total of 419 structural isomers, the ^{13}C NMR data sets for each structure were calculated, and the structures ranked on the basis of cumulative error between the calculated and experimental NMR values. The structure we proposed for eudistidine C (**1**) was the highest ranked structure identified by the Structure Elucidator software (Supporting Information).

While computer-assisted structure elucidation (CASE) provided a structure consistent with our proposal, we felt that additional evidence was required to complete the assignment due to the proton-deficient nature of **1**. The LR-HSQMBC experiment is a recently described NMR pulse sequence optimized to detect very long-range heteronuclear correlations.²⁴ It can be used to detect $^4J_{\text{CH}}$ and $^4J_{\text{NH}}$ correlations, and the utility of these long-range data was clearly demonstrated in the NMR characterization of cervinomycin A₂.²⁵ LR-HSQMBC is a high-sensitivity pulse sequence that optimizes responses for very small $^nJ_{\text{CH/NH}}$ couplings (≤ 0.2 Hz for $^nJ_{\text{CH}}$), and the resulting data complements experiments such as HMBC for defining structural elements that have few if any detectable protons. The HMBC experiment provides access to 2,3J correlations and only occasionally 4J heteronuclear correlations, while LR-HSQMBC data sets are populated with numerous four- and five-bond correlations.²⁶ These long-range correlations can help define structural elements with multiple quaternary carbons and heteroatoms, and link these moieties with protonated portions of the molecule. Crucial $^4J_{\text{CH}}$ and $^5J_{\text{CH}}$ correlations observed by LR-HSQMBC (Figure 2), including




Figure 2. Key four-bond (blue arrows) and five-bond (red arrows) ^1H – ^{13}C correlations measured with a 2 Hz optimized LR-HSQMBC experiment digitized with 768 F1 increments.

those from H-12/16 (ring E) to C-8a (ring D) and C-17 (ring G) as well as from H-23/27 and H-24/26 (ring F) to C-17, helped confirm the composition and connectivity of the rings in eudistidine C (**1**). When the LR-HSQMBC correlations were added to the data set used with the ACD/Structure Elucidator, the number of candidate structures was reduced from 419 to 335 and the total processing time was reduced from 247 to 35 s. As before, structure **1** was the highest ranked candidate.

Despite the valuable data obtained by the LR-HSQMBC experiment, no long-range correlations were ever recorded for C-19 or any of the nitrogen atoms associated with ring F. Thus, a portion of eudistidine C (**1**) remained only partially characterized, with inadequate spectroscopic data to fully define the structure. The synthesis of eudistidine C (**1**) was viewed as the best way to definitively prove its structure as well as provide access to useful quantities of **1** and its analogues. Inspection of **1** suggested it might arise from a dehydration-driven union of eudistidine A (**2**) and 3-arylaminimidazole **4**. We recently reported the preparation of **2** using a condensation/cyclization reaction cascade between 4-(2-aminophenyl)pyrimidin-2-amine and 4-(methoxyphenyl)glyoxal.²³ While this synthetic route was concise, isolation of the final product required a scale-limiting preparative HPLC step. We subsequently found that synthetic **2** can be isolated directly from the homogeneous reaction solution by simple addition of 1:1 acetone/hexanes to provide a solid product. This material is the HBr salt of **2** in sufficient purity to use




Figure 3. Synthesis of eudistidine C (1).




Figure 4. ^1H NMR spectral characteristics of eudistidine C (1) in CD_3OD : (A) synthetic eudistidine C TFA salt, (B) synthetic eudistidine C free base, (C) natural product eudistidine C free base form.

directly in the synthetic studies described below. Alternately, the solid material can be converted to its free base form through preparative HPLC in the presence of NH_4OH to give material with NMR spectral features identical to those of natural eudistidine A (2). This four-step, scalable preparation of eudistidine A (2) allowed us to investigate the coupling reaction to form eudistidine C (1) and other analogues. The aminoimidazole coupling partner needed to generate 1 was prepared in one step from the commercially available methyl ether through demethylation with BBr_3 to give the desired














phenol 4 (Experimental Section). The identity and purity of 4 were verified by NMR analysis (Supporting Information). After a screen of reaction conditions, we found the combination of the HBr salt of 2 and 4 (1.5 equiv) in DMSO at room temperature afforded racemic eudistidine C (1) in 64% yield following preparative HPLC (Figure 3). Notably, the free base of 2 does not undergo this reaction without additional acidic promotor. The synthetic material had NMR spectral features (^1H and ^{13}C) identical to those of the natural compound 1 when compared in their free base forms or when both spectra

were obtained in CD₃OD/0.1% TFA (Supporting Information). A 1:1 mixture of natural and synthetic eudistidine C provided a discrete set of ¹H and ¹³C NMR resonances, which confirmed the identical nature of these materials. Significant spectral differences were observed between the free base and salt forms of these alkaloids (Figure 4). Protonation state, counterion, and sample concentration can all be essential for accurate spectral comparison of natural and synthetic samples of complex heterocycles, such as the eudistidines.

The mild nature of this coupling procedure suggested that alternative nucleophiles might also add to the C-10 position of **2**. We first pursued this possibility with a variety of nucleophilic heteroarenes, including *N*-methylindole, 3-methylindole, and *N*-methylpyrrole. In all three cases, the corresponding adducts **5–7** could be obtained in useful preparative yield, although the reaction required extended heating at 40 °C in the case of 3-methylindole (Table 2). The connectivity of synthetic adducts was confirmed by 2D NMR, with heterocycle modification occurring at the expected site (C-3 of *N*-methylindole, C-2 of 3-methylindole, and C-2 of *N*-methylpyrrole). We further examined the reaction of **2** with phenol, resorcinol, and phloroglucinol. Compounds **8–10** were formed in suitable yields, albeit requiring extended heating in DMSO in the case of phenol and resorcinol. Following these results, the reactivity of **2** with various heteroatom nucleophiles was also evaluated. We found that with several representative alcohols, amines, and thiols, no new adducts could be isolated or observed by LCMS. Thus, it appears the electrophilic reactivity of **2** is confined to carbon nucleophiles. These initial studies generated a series of structural analogues of **1**, helped to characterize the reactivity of eudistidine A (**2**), and will enable future efforts to generate additional analogues of the eudistidine class of natural products.

Investigation of the UV absorption properties of eudistidine C (**1**) in MeOH revealed an absorption maximum at 403 nm. The UV/vis absorption profiles of **1** in aqueous solutions were quite similar to those recorded for eudistidine A (**2**),²³ as they exhibited pronounced pH-dependent spectral shifts. Local absorbance maxima for **1** were observed at 403 and 446 nm, with a hypsochromic shift in more acidic medium and an isosbestic point at approximately 420 nm (Supporting Information). Natural eudistidine C (**1**) is racemic, as it has no optical rotation [α]_D or Cotton effect in its CD spectrum, and the enantiomers are related by inversion at C-10. Eudistidine A (**2**) natural product is also racemic; however, it has a hemiaminal group at C-10, creating the likelihood that a ring D-opened minor tautomeric form of **2** facilitates rapid racemization at this position. The racemic nature of **1** and its inherent reactivity with nitrogen heteroaromatic compounds under mild conditions suggests that the final aminoimidazole coupling step in the biogenesis of eudistidine C (**1**) mirrors our synthetic strategy and may not necessarily occur via an enzymatic process. Ring D in **1** cannot open in a manner similar to **2**; thus, the two epimers at C-10 likely form during the nucleophilic coupling step and then are configurationally stable. The two enantiomers of the eudistidine C natural product racemate could be resolved by HPLC using a chiral-phase Lux Cellulose-4 analytical column (4.6 × 50 mm). The enantiomers in the natural product occurred as a 1:1 mixture with identical UV spectra but opposite sign Cotton effects when monitored at 240 nm (Supporting Information). Semipreparative separation (10 × 250 mm Lux-4 column) of synthetic eudistidine C provided the two enantiomers in pure form, and they showed equal magnitude but opposite sign

Table 2. Reaction of Eudistidine A (**2**) with Heteroarene and Arene Nucleophiles

		
Nucleophile	Conditions (yield)	Product
	1.5 equiv. Nuc DMSO, 24 h, rt (61%)	
	10 equiv. Nuc DMSO, 7 days, 40 °C (35%)	
	1.5 equiv. Nuc DMSO, 24 h, rt (56%)	
	40 equiv. Nuc DMSO, 6 days, 40 °C (27%)	
	12 equiv. Nuc DMSO, 24 h, 40 °C (62%)	
	9 equiv. Nuc DMSO, 24 h, rt (55%)	

Cotton effects in their ECD spectra (Figure 5). The early eluting enantiomer was assigned as (+)-(*R*)-eudistidine C (**1a**) by comparing its experimentally measured ECD spectrum with




Figure 5. Chiral-phase HPLC separation of racemic eudistidine C provided (+)-*R*-eudistidine C (**1a**) and (–)-*S*-eudistidine C (**1b**). (A) HPLC UV trace monitored at 210 nm of the racemate separated on a Lux Cellulose-4 column (chlorinated cellulose phenylcarbamate) provided two peaks (MH^+ , m/z 488) of approximately equal area. (B) ECD spectra of the early-eluting HPLC peak [blue; (+)-*R*-eudistidine C (**1a**)] and late-eluting peak [pink; (–)-*S*-eudistidine C (**1b**)] had equal magnitude but opposite sign Cotton effects.

the DFT-calculated spectrum (Figure 6). The late-eluting enantiomer was assigned as (–)-*S*-eudistidine C (**1b**) in a similar manner (Supporting Information). Eudistidine A (**2**) could also be resolved by chiral-phase HPLC into its two enantiomers. However, when the eluent of each peak was subsequently dried and reinjected on the HPLC two peaks of equal area were observed, indicating that ring opening and epimerization at C-10 had occurred.

Racemic eudistidine C (**1**) was tested in a dose–response version of the screening assay to assess its ability to block binding between the CH1 domain of p300 and the C-TAD domain of HIF-1 α . It showed approximately 48% inhibition of the protein–protein interaction at a high test concentration of 500 μ M. Testing of the individual enantiomers revealed that (–)-*S*-eudistidine C (**1b**) had an IC_{50} of 276 μ M, while

(+)-*R*-eudistidine C (**1a**) gave only 27% inhibition at 500 μ M. The eudistidine C analogues **5**–**10** were also evaluated in the HIF-1 α /p300 assay. The phloroglucinol adduct (**10**) was slightly more potent (IC_{50} = 141 μ M), while the *N*-methylindole (**5**), 3-methylindole (**6**), and *N*-methylpyrrole (**7**) derivatives had IC_{50} 's of 314, 399, and 356 μ M, respectively. The other analogues provided less than 50% inhibition at 500 μ M. In an effort to evaluate other biological properties, eudistidines A (**2**) and C (**1**) were tested in the NCI-60 panel of human tumor cell lines, but at an initial concentration of 40 μ M they were generally noncytotoxic and thus did not undergo further 60-cell testing.²⁷ Since a variety of different alkaloid structural families are known to have antimalarial properties, (+)-*R*-eudistidine C (**1a**), (–)-*S*-eudistidine C (**1b**), eudistidine A (**2**), and analogues **6**–**10**




Figure 6. Comparison of calculated (red) and experimentally measured (black) ECD spectra for (+)-(R)-eudistidine C (**1a**).

were also evaluated for inhibitory activity against chloroquine-sensitive (D6) and chloroquine-resistant (W2) strains of the *Plasmodium falciparum* parasite,²⁸ and all showed significant antimalarial effects (Supporting Information). The most potent were eudistidine A (**2**), which had IC_{50} values of 1.4 and 1.1 μ M, and the phloroglucinol analogue of eudistidine C (**10**), which had IC_{50} values of 1.1 and 0.6 μ M against the D6 and W2 strains, respectively.

CONCLUSION

The novel heptacyclic structure of eudistidine C was assigned using a combination of contemporary spectroscopic techniques and CASE analyses. The recently described LR-HSQMBC NMR pulse sequence with its ability to detect four- and five-bond heteronuclear correlations is particularly effective for assigning and verifying structural elements that are distant from protonated portions of a molecule. This technique was most applicable with eudistidine C (**1**), which has a severely proton-deficient central core region. A hallmark of virtually all natural products studies is the ability to define and verify the structure of the compounds of interest. As such, the continuing adaptation and application of new techniques such as NMR experiments that extend the sensitivity/boundaries for data acquisition are critically important. In addition, CASE programs such as ACD/Structure Elucidator are becoming more powerful and reliable, and they provide important tools that can be effectively utilized in challenging structural elucidation situations. The utility of CASE analysis was highlighted by congruence of the structure obtained from conventional interpretation of the spectroscopic data for eudistidine C with the most favored structural candidate revealed by the software. The new and often synergistic technologies now employed in natural products discovery have confirmed the tremendous untapped potential of this resource and sparked renewed interest in the chemical and biological diversity of secondary metabolites. In spite of recent advances, the architectural complexity and unusual functional group arrays found in some natural scaffolds still present structural elucidation challenges for noncrystalline secondary metabolites. The current study illustrates a range of contemporary structural elucidation strategies and techniques, including total synthesis, that were required to fully address structural questions associated with eudistidine C (**1**).

The new structural motif of eudistidine C (**1**) can be accessed in a single step by reaction of eudistidine A (**2**) with appropriate nucleophiles. The unusual propensity of eudistidine A to react irreversibly with aromatic carbon nucleophiles, but not with nucleophilic heteroatoms such as alkyl alcohols, amines, or thiols, provided a means to generate synthetic eudistidine C and also a variety of heteroarene and phenolic structural analogues (**5–10**). The effective synthesis of eudistidine C provided proof of its proposed structure and a means to supply an extremely mass-limited natural compound. Preparation of a series of structural analogues of **1** helped delineate the electrophilic reactivity of ring D and the hemiaminal moiety in eudistidine A (**2**) and also provided additional eudistidine type alkaloids for biological evaluation. Resolution of racemic eudistidine C into its two enantiomers allowed assignment and characterization of (+)-(R)-eudistidine C (**1a**) and (–)-(S)-eudistidine C (**1b**).

Initial biological characterization of eudistidine C suggests potential applications in the context of cancer and malaria. (–)-(S)-Eudistidine C (**1b**) and analogues **5–7** and **10** inhibited interaction of the protein-binding domains of the oncogenic transcription factor HIF-1 α and its coactivator p300, albeit only at relatively high concentrations. Small molecule inhibitors of tight protein–protein interactions are notoriously difficult to design or discover. Compounds based on the eudistidine framework represent possible chemical probes into the role of HIF-1 α and p300 in the adaptation of cancer cells to low oxygen environments and are leads for the development of cancer therapeutics. Compounds **1a**, **1b**, **2**, and **6–10** also inhibited chloroquine-sensitive and chloroquine-resistant strains of the malaria parasite *P. falciparum* at low micromolar concentrations. Treatment and prevention of malaria, and especially its drug-resistant variants, is a global health priority, and current drug therapies are inadequate. In total, compound **1** and its readily accessible structural analogues provide a potentially fruitful avenue for discovering novel antimalarial and cancer therapeutics.

EXPERIMENTAL SECTION

General Procedures. NMR spectra were obtained with an NMR spectrometer equipped with a 3 mm cryogenic probe and operating at 600 MHz for ^1H and 150 MHz for ^{13}C . ^1H – ^{13}C HMQC experiments were optimized for $J = 8.3$ Hz, and ^1H – ^{15}N HMQC experiments were optimized for $J = 8$ Hz. (+)HRESIMS data for **1** were acquired on a Q-TOF LC/MS. (+)HRESIMS data for **4–10** were conducted on a LTQ-Orbitrap hybrid mass spectrometer system with an API electrospray ion source in positive-ion mode. Preparative reversed-phase HPLC was run on a system using a C_{18} column (10 μ m, 110 Å, 75 \times 30 mm) with 0.1% TFA in the aqueous phase or a C_{18} column (5 μ m, 110 Å, 250 \times 9.4 mm) with 0.1% formic acid. IR spectra were acquired after MeOH solutions of the sample compounds were applied to a NaCl plate and the solvent was removed under a stream of N_2 , followed by high vacuum. The three-dimensional structure depicted in the TOC graphic was generated by molecular mechanics minimization using Spartan 14, and the representation was generated in CYL view.²⁹

Animal Material, Isolation, and Purification. Specimens of the ascidian *Eudistoma* sp. were collected at a depth range of –3 to –10 m on the Koror side of the collapsed Koror–Babeldaob Bridge in the Koror/Airai Channel, Palau (07°21.64' N, 134°30.17' E), in September 1998 by Dr. Patrick Colin, under contract through the Coral Reef Research Foundation for the Natural Products Branch, National Cancer Institute. Taxonomic identification of the ascidian was done by Francoise Monniot, and a voucher specimen (OCDN5649) was deposited at the Smithsonian Institute, Washington,

DC. The ascidian specimen (668 g, wet weight) was stored frozen until it was extracted according to the procedures detailed by McCloud³⁰ to give 7.2 g of organic solvent (CH₂Cl₂–MeOH, 1:1) extract. A portion of the organic extract (812.9 mg) was fractionated on two diol SPE cartridges (2 g) eluting with 9:1 hexane–CH₂Cl₂ (fraction A), 20:1 CH₂Cl₂–EtOAc (fraction B), 100% EtOAc (fraction C), 5:1 EtOAc–MeOH (fraction D), and 100% MeOH (fraction E) in a stepwise manner. Repeated size-exclusion LH-20 column chromatography of fraction E (439.5 mg) using MeOH as the eluent yielded eudistidine C (1, 10.7 mg, 1.32%).

Eudistidine C (1): yellow oil; UV (MeOH) λ_{\max} (log ϵ) 208 (4.36), 219 (4.30), 278 (4.32), 348 (3.40), 439 (3.45) nm; IR λ_{\max} 1646, 1626, 1504, 1351, 1246, 1167 cm^{−1}; ¹H and ¹³C NMR data, see Table 1; (+)HRESIMS m/z 488.1848 [M + H]⁺ (calcd for C₂₈H₂₁N₇O₂ 488.1829).

Synthesis of Eudistidine A (2) HBr Salt. The reaction to form eudistidine A (2) was run similarly to that reported previously, but the procedure was carried on a larger scale and the isolation procedure was significantly different.²³ A solution of 2-bromo-4'-methoxyacetophenone (620 mg, 2.7 mmol) in DMSO (15 mL) and water (1.5 mL) was heated at 65 °C for 3 h to generate 2-(4-methoxyphenyl)-2-oxoacetaldehyde. The solution was cooled to 4 °C before a solution of 4-(2-aminophenyl)pyrimidin-2-amine (300 mg, 1.8 mmol) in DMSO (2 mL) was added slowly. The resulting solution was heated at 60 °C for 1 h and then cooled back to 4 °C. I₂ (450 mg, 1.8 mmol) in DMSO (2 mL) was added slowly, and the brown solution was heated for an additional 1 h at 60 °C. The resulting solution was cooled to room temperature and then added to a stirring solution of 1:1 acetone–hexanes (250 mL). The red solid was filtered, washed (1:1 acetone–hexanes), and then collected and dried (480 mg, 65%). The compound could be subjected to reversed-phase HPLC employing a gradient of 20–60% MeCN/H₂O (1% NH₄OH) over 10 min to yield the free base form of eudistidine A (2) that by spectroscopic analysis was identical to the natural product.²³ The HBr salt of 2 was used in all the synthetic studies described below.

Eudistidine A (2) HBr salt: ¹H NMR (DMSO-*d*₆, 600 MHz) δ 9.21 (1H, d, J = 5.8 Hz, H-2), 8.99 (1H, d, J = 8.0 Hz, H-4), 8.40 (1H, d, J = 5.7 Hz, H-3), 8.28 (1H, t, J = 7.8 Hz, H-6), 8.23 (1H, d, J = 8.1 Hz, H-7), 8.17 (1H, br s, 10-OH), 8.10 (1H, t, J = 7.8 Hz, H-5), 7.71 (2H, d, J = 8.8 Hz, H-12/16), 7.05 (2H, d, J = 8.8 Hz, H-13/15), 3.79 (3H, s, 14-OCH₃); ¹³C NMR (DMSO-*d*₆, 150 MHz) δ 165.8 (C-2), 160.3 (C-14), 152.2 (C-8c), 151.8 (C-8a), 145.3 (C-3a), 144.9 (C-7a), 137.8 (C-6), 131.3 (C-5), 129.7 (C-7), 128.9 (C-11), 128.3 (C-12/16), 126.9 (C-4), 116.5 (C-3b), 113.8 (C-13/15), 103.2 (C-3), 88.7 (C-10), 55.4 (14-OCH₃). Anal. Calcd: C, 55.49; H, 3.68; Br, 19.43; N, 13.62. Found: C, 49.39; H, 6.24; Br, 16.45; N, 14.35.³¹

Synthesis of 4-(2-Amino-1H-imidazol-5-yl)phenol (4). 5-(4-Methoxyphenyl)-1H-imidazol-2-amine (100 mg, 0.53 mmol) was dissolved in CH₂Cl₂ (5 mL), and the solution was cooled to 0 °C. BBr₃ (1 M, 1.1 mL, 1.1 mmol) was added, and the reaction was allowed to warm to room temperature. H₂O (2 mL) was added slowly to the resulting heterogeneous mixture. The aqueous layer was loaded directly onto a C₁₈ column and eluted with a gradient of 5–95% MeCN–H₂O (no modifier) to provide 4-(2-amino-1H-imidazol-5-yl)phenol, as the HBr salt, as a white solid (100 mg, 70%):³² IR (thin film) λ_{\max} 3271, 3142, 3077, 1698, 1674, 1602, 1511, 1352, 1199 cm^{−1}; ¹H NMR (DMSO-*d*₆, 400 MHz) δ 12.1 (bs, 2H), 9.70 (s, 1H), 7.44 (d, 2H, J = 8.4 Hz), 7.31 (s, 2H), 7.15 (s, 1H), 6.81 (d, 2H, J = 8.4 Hz); ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 157.4, 147.2, 127.0, 125.9, 118.7, 115.6, 107.4; (+)HRESIMS m/z 176.0816 [M + H]⁺ (calc for C₉H₁₀N₃O 176.0818).

Synthesis of Eudistidine C (1). Eudistidine A HBr salt (20 mg, 0.048 mmol) was dissolved in DMSO (0.5 mL), and 4-(2-amino-1H-imidazol-5-yl)phenol (4, 15 mg, 0.072 mmol) was added. The solution was allowed to stand for 24 h. The solution was purified by reversed-phase preparative HPLC, employing a gradient of 5–95% MeCN/H₂O (0.1% TFA) over 10 min to yield eudistidine C (1, 18 mg, 64%): IR (thin film) λ_{\max} 3268, 3100, 1665, 1638, 1525, 1303, 1190 cm^{−1}; ¹H NMR (CD₃OD, 600 MHz) see the Supporting Information; ¹³C NMR (CD₃OD, 150 MHz) see the Supporting Information;

(+)HRESIMS m/z 488.1821 [M + H]⁺ (calcd for C₂₈H₂₂N₇O₂ 488.1829).

Synthesis of Eudistidine C N-Methylindole Analogue (5). Eudistidine A HBr salt (20 mg, 0.048 mmol) was dissolved in DMSO (0.5 mL), and N-methylindole (10 mg, 0.072 mmol) was added. The solution was stirred at 22 °C for 24 h and then purified by reversed-phase preparative HPLC, employing a gradient of 5–95% MeCN–H₂O (0.1% TFA) over 10 min to yield 5 (16 mg, 61%): IR (thin film) λ_{\max} 1664, 1638, 1511, 1256, 1172 cm^{−1}; ¹H NMR (CD₃OD, 600 MHz) δ 9.02 (1H, d, J = 5.8 Hz, H-2), 8.73 (1H, d, J = 8.0 Hz, H-4), 8.20 (1H, t, J = 7.7 Hz, H-6), 8.15 (1H, d, J = 8.1 Hz, H-7), 8.06 (1H, d, J = 5.6 Hz, H-3), 7.99 (1H, t, J = 7.7 Hz, H-5), 7.60 (2H, d, J = 8.5 Hz, H-12/16), 7.43 (1H, d, J = 8.3 Hz, H-21), 7.21 (2H, m, H-18, H-22), 7.13 (1H, d, J = 7.6 Hz, H-24), 6.98 (3H, m, H-13/15, H-23), 3.81 (3H, s, H-14OCH₃), 3.80 (3H, s, H-N19OCH₃); ¹³C NMR (CD₃OD, 150 MHz) δ 167.4 (C-2), 161.9 (C-14), 154.5 (C-8c), 154.3 (C-8a), 148.3 (C-3a), 147.0 (C-7a), 139.6 (C-20), 138.7 (C-6), 131.9 (C-5), 131.2 (C-11), 130.9 (C-7), 130.7 (C-18), 129.8 (C-12/16), 127.5 (C-4), 126.2 (C-25), 123.6 (C-22), 121.4 (C-24), 121.1 (C-23), 117.8 (C-3b), 115.3 (C-13/15), 114.0 (C-17), 111.0 (C-21), 103.5 (C-3), 71.5 (C-10), 55.9 (C-14OCH₃), 33.1 (C-N19OCH₃); (+)HRESIMS m/z 444.1806 [M + H]⁺ (calcd for C₂₈H₂₂N₅O 444.1819).

Synthesis of Eudistidine C 3-Methylindole Analogue (6). To a solution of eudistidine A HBr salt (5.2 mg, 0.013 mmol) in DMSO (1.0 mL) was added 3-methylindole (17 mg, 0.13 mmol). The orange/brown solution was stirred at 40 °C for 7 days, after which time the reaction was purified directly by preparative reversed-phase HPLC (5–95% MeCN/0.1% TFA/water). The product-containing fractions were concentrated in vacuo to afford 6 (2.5 mg, 35% yield) as a brown solid: IR (thin film) λ_{\max} 3179, 1664, 1638, 1512, 1305, 1176 cm^{−1}; ¹H NMR (CD₃OD, 600 MHz) δ 9.04 (1H, d, J = 5.9 Hz, H-2), 8.76 (1H, d, J = 8.1 Hz, H-4), 8.23 (1H, m, H-6), 8.21 (1H, m, H-7), 8.10 (1H, d, J = 5.8 Hz, H-3), 8.02 (1H, m, H-5), 7.70 (2H, d, J = 8.7 Hz, H-12/16), 7.51 (1H, d, J = 8.1 Hz, H-23), 7.25 (1H, d, J = 8.1 Hz, H-20), 7.13 (1H, t, J = 7.6 Hz, H-21), 7.07 (2H, d, J = 8.7 Hz, H-13/15), 7.04 (1H, t, J = 7.6 Hz, H-22), 3.84 (3H, s, 14-OCH₃), 1.91 (3H, s, 25-CH₃); ¹³C NMR (CD₃OD, 150 MHz) δ 167.5 (C-2), 162.2 (C-14), 154.4 (C-8c), 153.7 (C-8a), 148.3 (C-3a), 147.0 (C-7a), 138.8 (C-6), 137.5 (C-19), 132.2 (C-5), 131.1 (C-7), 130.6 (C-17), 130.5 (C-11), 130.5 (C-24), 129.7 (C-12/16), 127.5 (C-4), 124.2 (C-21), 120.5 (C-22), 119.8 (C-23), 117.9 (C-3b), 115.6 (C-13/15), 112.7 (C-25), 112.2 (C-20), 103.7 (C-3), 71.6 (C-10), 55.9 (14-OCH₃), 9.5 (25-CH₃); (+)HRESIMS m/z 444.1808 [M + H]⁺ (calcd for C₂₈H₂₂N₅O 444.1819).

Synthesis of Eudistidine C N-Methylpyrrole Analogue (7). Eudistidine A HBr salt (20 mg, 0.048 mmol) was dissolved in DMSO (0.5 mL), and N-methylpyrrole (6 mg, 0.072 mmol) was added. The solution was stirred at 22 °C for 24 h and then purified by reversed-phase preparative HPLC, employing a gradient of 5–95% MeCN–H₂O (0.1% TFA) over 10 min to yield 7 (13 mg, 56%): IR (thin film) λ_{\max} 1663, 1638, 1510, 1301, 1256, 1177 cm^{−1}; ¹H NMR (CD₃OD, 600 MHz) δ 9.01 (1H, d, J = 5.3 Hz, H-2), 8.74 (1H, d, J = 7.7 Hz, H-4), 8.23 (1H, t, J = 7.9 Hz, H-6), 8.20 (1H, d, J = 8.1 Hz, H-7), 8.06 (1H, d, J = 5.3 Hz, H-3), 8.01 (1H, t, J = 7.8 Hz, H-5), 7.42 (2H, d, J = 8.8 Hz, H-12/16), 7.04 (2H, d, J = 8.8 Hz, H-13/15), 6.82 (1H, br t, J = 2.2 Hz, H-19), 6.26 (1H, m, H-21), 6.09 (1H, br t, J = 3.3 Hz, H-20), 3.82 (3H, s, H-14OCH₃), 3.45 (3H, s, H-N18OCH₃); ¹³C NMR (CD₃OD, 150 MHz) δ 167.4 (C-2), 162.2 (C-14), 154.3 (C-8c), 153.2 (C-8a), 148.4 (C-3a), 146.7 (C-7a), 138.8 (C-6), 132.2 (C-5), 130.9 (C-7), 130.6 (C-11), 129.6 (C-12/16), 128.9 (C-17), 128.2 (C-19), 127.6 (C-4), 117.8 (C-3b), 115.7 (C-13/15), 112.8 (C-21), 108.1 (C-20), 103.8 (C-3), 71.4 (C-10), 55.9 (C-14OCH₃), 36.4 (C-N18OCH₃); (+)HRESIMS m/z 394.1656 [M + H]⁺ (calcd for C₂₄H₂₀N₅O 394.1662).

Synthesis of Eudistidine C *p*-Phenol Analogue (8). To a solution of eudistidine A HBr salt (6.0 mg, 0.014 mmol) in DMSO (0.3 mL) was added phenol (53 mg, 0.57 mmol). The orange/brown solution was stirred at 40 °C for 6 days, after which time the reaction was purified directly by preparative reversed-phase HPLC employing a

gradient of 10–95% MeCN/H₂O (0.1% formic acid) over 8 min. The product-containing fractions were concentrated in vacuo to afford **8** (1.8 mg, 27% yield) as a yellow solid: IR (thin film) λ_{max} 3100, 1663, 1639, 1509, 1303, 1180 cm⁻¹; ¹H NMR (CD₃OD, 600 MHz) δ 8.44 (1H, d, J = 5.0 Hz, H-2), 8.22 (1H, d, J = 7.7 Hz, H-4), 7.89 (1H, m, H-6), 7.87 (1H, m, H-7), 7.66 (1H, m, H-5), 7.44 (2H, d, J = 9.4 Hz, H-12/16), 7.34 (2H, d, J = 9.5 Hz, H-18/22), 6.90 (2H, d, J = 8.8 Hz, H-13/15), 6.78 (1H, d, J = 5.1 Hz, H-3), 6.76 (2H, d, J = 8.5 Hz, H-19/21), 3.77 (3H, s, 14-OCH₃); ¹³C NMR (CD₃OD, 150 MHz) δ 167.4 (C-2), 162.5 (C-8a), 160.7 (C-14), 158.3 (C-20), 156.3 (C-8c), 147.6 (C-7a), 147.5 (C-3a), 136.4 (C-6), 135.9 (C-11), 134.6 (C-17), 129.9 (C-7), 129.8 (C-5), 129.8 (C-12/16), 129.8 (C-18/22), 126.3 (C-4), 117.9 (C-3b), 116.1 (C-19/21), 114.7 (C-13/15), 93.7 (C-3), 79.6 (C-10), 55.7 (14-OCH₃); (+)HRESIMS m/z 407.1497 [M + H]⁺ (calcd for C₂₅H₁₉N₄O₂ 407.1503).

Synthesis of Eudistidine C Resorcinol Analogue (9). To a solution of eudistidine A HBr salt (10 mg, 0.025 mmol) in DMSO (0.5 mL) was added resorcinol (31 mg, 0.29 mmol). The orange/brown solution was stirred at 40 °C for 24 h, after which time the reaction was purified directly by preparative reversed-phase HPLC employing a gradient of 10–95% MeCN/H₂O (0.1% formic acid) over 8 min. The product-containing fractions were concentrated in vacuo to afford **9** (7.2 mg, 62% yield) as a yellow solid: IR (thin film) λ_{max} 3100, 1662, 1640, 1527, 1303, 1258, 1185 cm⁻¹; ¹H NMR (DMSO-*d*₆, 600 MHz) δ 8.42 (1H, d, J = 4.7 Hz, H-2), 8.28 (1H, d, J = 7.8 Hz, H-4), 7.86 (1H, t, J = 7.5 Hz, H-6), 7.78 (1H, d, J = 8.1 Hz, H-7), 7.65 (2H, d, J = 8.8 Hz, H-12/16), 7.61 (1H, t, J = 7.5 Hz, H-5), 6.96 (2H, d, J = 9.1 Hz, H-13/15), 6.68 (1H, d, J = 8.8 Hz, H-18), 6.79 (1H, d, J = 4.9 Hz, H-3), 6.16 (1H, d, J = 2.3 Hz, H-21), 6.14 (1H, dd, J = 8.7, 2.5 Hz, H-19), 3.74 (3H, s, 14-OCH₃); ¹³C NMR (DMSO-*d*₆, 150 MHz) δ 165.9 (C-2), 162.9 (C-8a), 158.7 (C-14), 158.2 (C-20), 156.9 (C-22), 154.4 (C-8c), 145.8 (C-7a), 145.3 (C-3a), 134.9 (C-6), 133.0 (C-11), 128.8 (C-18), 128.7 (C-12/16), 128.3 (C-7), 128.0 (C-5), 125.3 (C-4), 119.7 (C-17), 116.6 (C-3b), 113.5 (C-13/15), 105.6 (C-19), 103.1 (C-21), 91.7 (C-3), 76.1 (C-10), 55.1 (14-OCH₃); (+)HRESIMS m/z 423.1446 [M + H]⁺ (calcd for C₂₅H₁₉N₄O₃ 423.1452).

Synthesis of Eudistidine C Phloroglucinol Analogue (10). To a solution of eudistidine A HBr salt (5.6 mg, 0.014 mmol) in DMSO (1.0 mL) was added phloroglucinol (16.4 mg, 0.130 mmol). The orange/brown solution was stirred at 22 °C for 24 h, after which time the reaction was purified directly by preparative reversed-phase HPLC (5–95% MeCN/0.1% TFA/water). The product-containing fractions were concentrated in vacuo to afford **10** (4.2 mg, 55% yield) as a yellow solid: IR (thin film) λ_{max} 3101, 1672, 1627, 1562, 1257, 1183 cm⁻¹; ¹H NMR (CD₃OD, 600 MHz) δ 8.77 (1H, d, J = 5.2 Hz, H-2), 8.12 (1H, d, J = 8.1 Hz, H-4), 7.63 (1H, t, J = 7.4 Hz, H-6), 7.52 (1H, d, J = 5.3 Hz, H-3), 7.41 (2H, d, J = 8.9 Hz, H-12/16), 7.19 (1H, t, J = 7.8 Hz, H-5), 7.12 (1H, d, J = 8.4 Hz, H-7), 7.01 (2H, d, J = 8.9 Hz, H-13/15), 6.07 (1H, d, J = 1.9 Hz, H-21), 5.85 (1H, d, J = 1.9 Hz, H-19), 3.63 (3H, s, 14-OCH₃); ¹³C NMR (CD₃OD, 150 MHz) δ 168.3 (C-2), 163.3 (C-20), 162.0 (C-14), 160.6 (C-18), 157.1 (C-22), 156.5 (C-8c), 149.2 (C-3a), 144.6 (C-7a), 138.4 (C-6), 130.4 (C-12/16), 127.7 (C-4), 126.8 (C-11), 123.1 (C-5), 118.7 (C-7), 115.0 (C-13/15), 111.6 (C-3b), 104.4 (C-3), 103.3 (C-17), 98.5 (C-21), 90.6 (C-19), 78.6 (C-10), 55.8 (14-OCH₃), not observed (C-8a); (+)HRESIMS m/z 439.1392 [M + H]⁺ (calcd for C₂₅H₁₉N₄O₄ 439.1401).

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b02380.

¹H NMR, ¹³C NMR, COSY, HSQC, HMBC, and LR-HSQMBC data and UV–vis data for compound **1**. ¹H NMR and ¹³C NMR data for compounds **5–10**. ACD/Structure Elucidator generation results and table of atomic coordinates for compound **1**. ECD spectra for compounds **1a** and **1b**. p300/HIF-1 α and antimalaria testing data for compounds **1a,b**, **2**, **5–10** (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: martin.schnermann@nih.gov.

*E-mail: gustafki@mail.nih.gov.

ORCID

Alexei V. Buevich: 0000-0002-5968-9151

Present Addresses

[§](T.C.M.) Diagnostic Biomarkers and Technology Branch, Cancer Diagnosis Program, DCTD, National Cancer Institute, Bethesda, MD 20850.

[&](E.A.S.) Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We gratefully acknowledge D. Newman (NCI) for organizing and documenting the collection, the Natural Products Support Group at NCI—Frederick for extraction, T. Bostaph (MTL) and K. Goncharova (MTL) for screening data compilation and analysis, J. Barchi (CBL) for NMR assistance, J. Kelly (CBL) for mass spectrometry analysis, and S. Tarasov and M. Dyba (Biophysics Resource Core, Structural Biophysics Laboratory, CCR) and H. Bokesch (MTL) for assistance with high-resolution mass spectrometry. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. This project was also funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E and by the USDA Agricultural Research Service Specific Cooperative Agreement No. 58-6408-1-603. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

■ REFERENCES

- (1) Newman, D. J.; Cragg, G. M. *J. Nat. Prod.* **2016**, *79*, 629–661.
- (2) Ling, L. L.; Schneider, T.; Peoples, A. J.; Spoering, A. L.; Engels, I.; Conlon, B. P.; Mueller, A.; Schäberle, T. F.; Hughes, D. E.; Epstein, S.; Jones, M.; Lazarides, L.; Steadman, V. A.; Cohen, D. R.; Felix, C. R.; Fetterman, K. A.; Millett, W. P.; Nitti, A. G.; Zullo, A. M.; Chen, C.; Lewis, K. *Nature* **2015**, *517*, 455–459.
- (3) Harvey, A. L.; Edrada-Ebel, R.; Quinn, R. J. *Nat. Rev. Drug Discovery* **2015**, *14*, 111–129.
- (4) Newman, D. J.; Cragg, G. M. *Mar. Drugs* **2014**, *12*, 255–278.
- (5) Steinmetz, H.; Li, J.; Fu, C.; Zaburanyi, N.; Kunze, B.; Harmrolfs, K.; Schmitt, V.; Herrmann, J.; Reichenbach, H.; Höfle, G.; Kalesse, M.; Müller, R. *Angew. Chem., Int. Ed.* **2016**, *55*, 10113–10117.
- (6) Tadesse, M.; Strøm, M. B.; Svenson, J.; Jaspars, M.; Milne, B. F.; Tørfoss, V.; Andersen, J. H.; Hansen, E.; Stensvåg, K.; Haug, T. *Org. Lett.* **2010**, *12*, 4752–4755.
- (7) Avilés, E.; Rodríguez, A. D. *Org. Lett.* **2010**, *12*, 5290–5293.
- (8) Sueyoshi, K.; Kaneda, M.; Sumimoto, S.; Oishi, S.; Fujii, N.; Suenaga, K.; Teruya, T. *Tetrahedron* **2016**, *72*, 5472–5478.
- (9) Walsh, C. T. *Nat. Chem. Biol.* **2015**, *11*, 620–624.
- (10) Doroghazi, J. R.; Albright, J. C.; Goering, A. W.; Ju, K.-S.; Haines, R. R.; Tchalukov, K. A.; Labeda, D. P.; Kelleher, N. L.; Metcalf, W. W. *Nat. Chem. Biol.* **2014**, *10*, 963–968.
- (11) Starcevic, A.; Zucko, J.; Simunkovic, J.; Long, P. F.; Cullum, J.; Hranueli, D. *Nucleic Acids Res.* **2008**, *36*, 6882–6892.
- (12) Molinski, T. F. *Curr. Opin. Biotechnol.* **2010**, *21*, 819–826.
- (13) Molinski, T. F. *Nat. Prod. Rep.* **2010**, *27*, 321–329.

- (14) Hilton, B. D.; Martin, G. E. *J. Nat. Prod.* **2010**, *73*, 1465–1469.
- (15) Saurí, J.; Bermel, W.; Buevich, A. V.; Sherer, E. C.; Joyce, L. A.; Sharaf, M. H. M.; Schiff, P. L., Jr.; Parella, T.; Williamson, R. T.; Martin, G. E. *Angew. Chem., Int. Ed.* **2015**, *54*, 10160–10164.
- (16) Paudel, L.; Adams, R. W.; Király, P.; Aguilar, J. A.; Foroozandeh, M.; Cliff, M. J.; Nilsson, M.; Sándor, P.; Waltho, J. P.; Morris, G. A. *Angew. Chem., Int. Ed.* **2013**, *52*, 11616–11619.
- (17) Liu, Y.; Green, M. D.; Marques, R.; Pereira, T.; Helmy, R.; Williamson, R. T.; Bermel, W.; Martin, G. E. *Tetrahedron Lett.* **2014**, *55*, 5450–5453.
- (18) Halabalaki, M.; Vougiannopoulou, K.; Mikros, E.; Skaltsounis, A. L. *Curr. Opin. Biotechnol.* **2014**, *25*, 1–7.
- (19) Elyashberg, M. E.; Williams, A. J.; Martin, G. E. Computer-Assisted Structure Elucidation. In *Progress in NMR Spectroscopy*; Feeney, J., Sutcliffe, L., Eds.; Pergamon: London, 2008; Vol. 53, pp 1–104.
- (20) Plainchont, B.; de Paulo Emerenciano, V.; Nuzillard, J.-M. *Magn. Reson. Chem.* **2013**, *51*, 447–453.
- (21) Moser, A.; Elyashberg, M. E.; Williams, A. J.; Blinov, K. A.; DiMartino, J. C. *J. Cheminf.* **2012**, *4*, 5.
- (22) Naman, C. B.; Li, J.; Moser, A.; Hendrycks, J. M.; Benatrehina, P. A.; Chai, H.; Yuan, C.; Keller, W. J.; Kinghorn, A. D. *Org. Lett.* **2015**, *17*, 2988–2991.
- (23) Chan, S. T.; Patel, P. R.; Ransom, T. R.; Henrich, C. J.; McKee, T. C.; Goey, A. K.; Cook, K. M.; Figg, W. D.; McMahon, J. B.; Schnermann, M. J.; Gustafson, K. R. *J. Am. Chem. Soc.* **2015**, *137*, 5569–5575.
- (24) Williamson, R. T.; Buevich, A. V.; Martin, G. E.; Parella, T. *J. Org. Chem.* **2014**, *79*, 3887–3894.
- (25) Blinov, K. A.; Buevich, A. V.; Williamson, R. T.; Martin, G. E. *Org. Biomol. Chem.* **2014**, *12*, 9505–9509.
- (26) Lorenc, C.; Saurí, J.; Moser, A.; Buevich, A. V.; Williams, A. J.; Williamson, R. T.; Martin, G. E.; Pecuh, M. W. *ChemistryOpen* **2015**, *4*, 577–580.
- (27) Shoemaker, R. H. *Nat. Rev. Cancer* **2006**, *6*, 813–823.
- (28) Makler, M. T.; Hinrichs, D. J. *Am. J. Trop. Med. Hyg.* **1993**, *48*, 205–210.
- (29) Legault, C. Y. *CYLview, 1.0b*; Université de Sherbrooke, 2009, <http://www.cylview.org>
- (30) McCloud, T. G. *Molecules* **2010**, *15*, 4526–4563.
- (31) The elemental analysis indicates the inclusion of bromine, but not proof of molecular formula, which was conclusively demonstrated in ref 23.
- (32) Nath, J. P.; Mahapatra, G. N. *Indian J. Chem., Sect. B* **1980**, *19B*, 536–538.